Regenxbio Inc (FRA:RB0)
€ 11.7 0.2 (1.72%) Market Cap: 582.38 Mil Enterprise Value: 351.37 Mil PE Ratio: 0 PB Ratio: 1.62 GF Score: 65/100

Regenxbio Inc at Barclays Gene Editing & Gene Therapy Summit (Virtual) Transcript

Nov 15, 2021 / 06:30PM GMT
Release Date Price: €32.04 (-1.60%)
Huidong Wang
Barclays Bank PLC, Research Division - Research Analyst

Good afternoon, everyone. My name is Gena Wang. I'm SMID-cap biotech analyst at Barclays. Welcome to our fifth Gene Editing and Gene Therapy Summit. It is my great pleasure to introduce our next speaker, Ken Mills, Chief Executive Officer from REGENXBIO. Ken, I will hand over to you.

Kenneth T. Mills
REGENXBIO Inc. - President, CEO & Director

Gena, thanks very much, and thanks to you and the Barclays team for inviting us to this event. We always enjoy spending time talking about REGENXBIO and things happening in the field. And a few slides that I'm going to bring up here to give a quick overview, and then I know we'll transition into a discussion-based format. I'll get my technology working.

Thanks. Before I get into the background, I just want to acknowledge the forward-looking statement disclaimer here on the second slide that there may be some discussion of factors that relate to forward-looking statements on my part during this quick talk and discussion.

REGENXBIO

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot